主页 > 医学新闻 >
【medical-news】卡维地洛可以预防蒽环类抗生素引
NEW YORK (Reuters Health) Dec 15 - Carvedilol protects patients against the development of anthracycline-induced cardiomyopathy, an irreversible condition that may occur at any time during anthracycline treatment.
"According to our study results, carvedilol shows promising effect on preventing anthracycline-induced cardiomyopathy," Dr. Nihat Kalay from Erciyes University School of Medicine, Kayseri, Turkey told Reuters Health. "If our results are supported by further studies, carvedilol may be used in clinic practice to prevent this important health problem."
Dr. Kalay and colleagues investigated whether carvedilol had cardiac protective effects in 50 patients diagnosed with cancer and planned to have anthracycline therapy (doxorubicin or epirubicin). The patients were randomized to receive carvedilol (25 mg once-daily) plus an anthracycline therapy or to a placebo plus an anthracycline.
Although the treatment and placebo groups started with similar mean ejection fractions, the authors report, patients in the placebo group had a lower ejection fraction at the end of follow-up, whereas carvedilol-treated patients experienced no loss in mean ejection fraction.
Similarly, carvedilol patients showed no significant change in systolic and diastolic left ventricular diameters, but control group patients had significant increases in both systolic and diastolic diameters.
"Four patients died in the control group, and only one patient died in the carvedilol group," the investigators report in the December 5th Journal of the American College of Cardiology. "Although not reaching statistical significance, we suggest that the higher mortality rate in the control group may have clinical importance."
"The reason for the cardioprotective effects of carvedilol in anthracycline-induced cardiomyopathy is not fully known," the researchers explain. "However, cardioprotection may occur through the potent antioxidant activity of carvedilol."
"We plan to investigate whether carvedilol prophylaxis improved late-term survival," Dr. Kalay said.
"In my opinion, all physicians must be careful in preventing, diagnosing and treating anthracycline-induced cardiomyopathy," Dr. Kalay added. --Preventing disease is easier than trying to treat it.
http://www.medscape.com/viewarticle/549492 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领。 Carvedilol Prevents Anthracycline-Induced Cardiomyopathy
卡维地洛可以预防蒽环类抗生素引起的心肌病
NEW YORK (Reuters Health) Dec 15 - Carvedilol protects patients against the development of anthracycline-induced cardiomyopathy, an irreversible condition that may occur at any time during anthracycline treatment.
纽约(路透社健康新闻部)12月15日 -卡维地洛能够将蒽环类抗生素引起的心肌病扼杀在摇篮阶段，保护病人免受心肌病的困扰。心肌病是服用蒽环类抗生素后随时可能出现的一种不可逆的疾病。
"According to our study results, carvedilol shows promising effect on preventing anthracycline-induced cardiomyopathy," Dr. Nihat Kalay from Erciyes University School of Medicine, Kayseri, Turkey told Reuters Health. "If our results are supported by further studies, carvedilol may be used in clinic practice to prevent this important health problem."
"根据我们的研究结果,卡维地洛对防止蒽环类抗生素引起的心肌病效果显著", 来自土耳其Kayseri的Erciyes大学医学院的Nihat Kalay博士，在接受路透社健康新闻部记者采访时说道，"如果我们的结果得到进一步研究的证实，卡维地洛就有可能用于临床以防止出现这一严重的健康问题。”
Dr. Kalay and colleagues investigated whether carvedilol had cardiac protective effects in 50 patients diagnosed with cancer and planned to have anthracycline therapy (doxorubicin or epirubicin). The patients were randomized to receive carvedilol (25 mg once-daily) plus an anthracycline therapy or to a placebo plus an anthracycline.
Kalay博士和其同事的研究对象是50位准备接受蒽环类抗生素治疗(阿霉素或者表柔比星)的癌症病人，目的是观察卡维地洛对这些病人的心脏是否有保护作用。他们将病人随机分成两组，在两组都接受蒽环类抗生素治疗的基础上，一组外加服用卡维地洛（25毫克，一次/每日）；另一组则服用安慰剂。
Although the treatment and placebo groups started with similar mean ejection fractions, the authors report, patients in the placebo group had a lower ejection fraction at the end of follow-up, whereas carvedilol-treated patients experienced no loss in mean ejection fraction.
Kalay博士指出，虽然一开始，卡维地洛治疗组和安慰剂对照组的平均心脏射血指数差不多，但安慰剂组的病人在治疗后期的心脏射血指数相对较低，反观卡维地洛治疗组病人，其平均心脏射血指数未见任何下降。
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-04-06 14:04
医学,生命科学网